Nothing said here yet.
to join the conversation.
| Boyle DanaChief Accounting Officer | Sell | 1,581 | $68.3K | Mon, Oct 26 |
| Adair JasonChief Business Officer | Sell | 688 | $29.7K | Mon, Oct 26 |
| JEFFS ROGERChief Executive Officer | Sell | 32,744 | $932.5K | Mon, Oct 12 |
| Kaseta MichaelCFO and COO | Sell | 18,938 | $539.4K | Mon, Oct 12 |
| Schundler RussellGeneral Counsel | Sell | 13,692 | $389.9K | Mon, Oct 12 |
| Saggar RajeevChief Medical Officer | Sell | 9,218 | $262.5K | Mon, Oct 12 |
| Moomaw ScottChief Commercial Officer | Sell | 8,863 | $252.4K | Mon, Oct 12 |
| Adair JasonChief Business Officer | Sell | 7,301 | $207.9K | Mon, Oct 12 |
| Boyle DanaChief Accounting Officer | Sell | 5,892 | $167.8K | Mon, Oct 12 |
| Krepp SarahChief Human Resource Officer | Sell | 5,245 | $149.4K | Mon, Oct 12 |
| Khindri SanjeevChief Development Officer | Sell | 1,101 | $31.4K | Mon, Oct 12 |
| Bloch Stephen MDirector | Sell | 235,477 | $6.4M | Mon, Oct 5 |
For questions about this article or underlying research, email [email protected].
LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liquidia has seen sharp swings in recent years, and the question now is whether the current share price lines up with what its earnings can reasonably support.
United Therapeutics (UTHR) faces limited near-term upside for Tyvaso following the Liquidia (LQDA) s
Liquidia recently reached a global settlement with United Therapeutics, resolving six lawsuits and allowing its YUTREPIA therapy for pulmonary arterial hypertension to remain on the market while agreeing to remove the pulmonary hypertension due to…
Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%.
Liquidia stock rallies on a settlement with United Therapeutics. But is it already too late to invest in LQDA shares?
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes.
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.